Christophe Bailleul - Mauna Kea Insider

MKEA -- France Stock  

EUR 2.92  0.045  1.57%

Vice-President Clinical Affairs, Health Economics and Market Access

Mr. Christophe Bailleul is VicePresident Clinical Affairs, Health Economics and Market Access of Mauna Kea Technologies SAS. He joined Mauna Kea Technologies in 2015 and brings a wealth of clinical knowledge to the company with more than 25 years of international experience in the biotech and medical device sectors. He started his career in a French biotech startup affiliate of the National Blood Transfusion Foundation in the late 80s. He then spent 5 years in Germany as a research and quality assurance manager in a young CRO, PRA International. He also worked in the clinical development field at Ela Medical, which is part of Sorin Group. From 2002 on he was based in Belgium as the VP of Clinical Affairs and Health Economics of the International Division at St. Jude Medical. He holds multiple academic degrees including, an engineering degree from the Universite de technologie de Compiegne in France, an MSc in blood transfusion and immunology, a PhD in immunobiotechnologies and an MBA from ESSEC in Paris, France.
  President Since 2015  MBA    
33 1 48 24 03 45  http://www.maunakeatech.com

Management Efficiency

The company has return on total asset (ROA) of (35.99) % which means that it has lost $35.99 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (123.6) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 6.82 M in total debt with debt to equity ratio (D/E) of 83.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Mauna Kea Technologies SA has Current Ratio of 3.35 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

Mauna Kea Technologies SA, a medical device company, develops and sells endomicroscopy and optical biopsy for the diagnosis and treatment of cancer and other diseases. The company was founded in 2000 and is headquartered in Paris, France. Mauna Kea operates under Medical Equipment classification in France and traded on Paris Stock Exchange.Mauna Kea Technologies SA (MKEA) is traded on Paris Stock Exchange in France. It is located in 9, rue d'Enghien and employs 81 people.

Mauna Kea Technologies Leadership Team

Olivier Regnard, CEO
Bertrand Talhouet, Director
Eric Cohen, CFO, MBA
Gilles Brisson, Chairman
Alexandre Loiseau, CEO, Ph.D
Guillaume Bailliard, President, MBA
Christopher McFadden, Director, CFA
Francois Lacombe, Executive, Ph.D
Christopher Tihansky, President, MBA
JeanLuc Boulnois, Director, MBA
Bruno Villaret, President
Joseph DeVivo, Director
Christophe Bailleul, President, MBA
Agnes Rouffiac, Director
Veronique Dentan, Director
Sebastien Cadet, Director
Sacha Loiseau, CEO, Ph.D
Molly ONeill, Director
Pierre Forest, COO
John Soto, COO
Marie Meynadier, Director

Stock Performance Indicators

Did you try this?

Run Portfolio Backtesting Now
   

Portfolio Backtesting

Avoid under-diversification and over-optimization by backtesting your portfolios
All  Next Launch Portfolio Backtesting

Generate Optimal Portfolios

Align your risk and return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Commodity Channel Index module to use commodity channel index to analyze current equity momentum.